Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGF-Endoret infiltrations in low back pain
2023-507429-41-00Phase 4Authorised
- Sponsor
- BTI Biotechnology Institute
- Start
- Sep 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of PRGF-Endoret in lumbodynia (LBP) and lumbar intervertebral disc degenerative disease (LDDD) (2 arms), sponsored by BTI Biotechnology Institute. Primary endpoint: Oswestry Disability Index at 6 months. Planned start Sep 2024; status: authorised.
02
Drugs
PRGF-Endoret
03
Conditions
lumbodynia (LBP)lumbar intervertebral disc degenerative disease (LDDD)
Beyond the preview
Go deeper on 2023-507429-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507429-41-00.